CRISPR Therapeutics price to book ratio CRSP

Market value divided by the book value of the company's net assets, since 2017.

Today, Oct 23, 2026: 2.7×
10-year median: 3.0×
Against its 10-year history: 40th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.4× to 14.2×
Peer median: 5.6×

CRISPR Therapeutics' price to book ratio is 2.7× as of Oct 23, 2026.

That is below its ten-year median of 3.0×, close to the middle of its last ten years.

Over that time it ranged from 1.4× in Apr 2025 to 14.2× in Mar 2018.

The median for 10 biotech stocks of a similar size is 5.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.7×	2.3×	3.3×
2025	2.7×	1.4×	3.9×
2024	1.8×	1.8×	3.8×
2023	2.9×	1.7×	3.2×
2022	1.6×	1.5×	2.9×
2021	2.3×	2.1×	10.5×
2020	8.1×	2.4×	8.9×
2019	6.2×	3.8×	7.4×
2018	3.3×	2.8×	14.2×
2017	5.4×	2.6×	5.4×

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

Company	Price to book ratio
CRSPCRISPR Therapeutics	2.7×
KRYSKrystal Biotech	6.8×
ADMAAdma Biologics	5.9×
RGENRepligen	4.7×
VCELVericel	5.9×
TECHBIO-TECHNE	5.4×
HALOHalozyme Therapeutics	99.3×
NBIXNeurocrine Biosciences	3.9×
EXELExelixis	8.7×
INCYIncyte	3.7×
UTHRUnited Therapeutics	3.9×
Peer median	5.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.